References
- Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Sub-committee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997; 24: 235–47.
- Abi-Said D, Anaissie E, Uzun 0, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122–8.
- Nguyen MH, Clancy CJ, Yu VL, et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 1998; 177: 425–30.
- Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Ant imicrob Agents Chemother 1993; 37: 1847–9.
- Colombo AL, Nucci M, Salomao R, et al. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999; 34: 281–6.
- National Committee for Clinical Laboratory Standards. Reference Method for Broth dilution. Antifungal Susceptibility Testing of Yeasts; Approved Standard. Document M27-A 17, 1–29, 1997.
- Pfaller MA, Jones RN, Doem GV, et al. Blood stream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Ant imicrob Agents Chemother 2000; 44: 747–51.
- Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20: 115–25.
- Pliego-Castaneda A, Yanez-Viguri A, Lopez-Valle T, Valdes-de la Torre F. Prevalence and sensitivity of Candida albicans in cultures obtained at an oncologic hospital. Gac Med Mex 2000; >136: 193–9.
- Stevens DA, Stevens JA. Cross-resistance phenotypes of flucona-zole-resistant Candida species: results with 655 clinical isolates with different methods. Diagn Microbiol Infect Dis 1996; >26: 145–8.
- Pfaller MA, Jones RN, Doern GV, et al. International surveil-lance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echino-candin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis 1999; >35: 19–25.
- Pfaller MA, Diekema DJ, Jones RN, et al. International Surveillance of Bloodstream Infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol 2001; >39: 3254–9.
- Safdar A, Chaturvedi V, Cross EW, et al. Prospective study of Candida species in patients at a comprehensive cancer center. Ant imicrob Agents Chemother 2001; >45: 2129–33.
- St Germain G, Laverdière M, Pelletier R, et al. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Micro-biol 2001; >39: 949–53.
- Barchiesi F, Arzeni D, Caselli F, Scalise G. Primary resistance to flucytosine among clinical isolates of Candida spp. J Ant imicrob Chemother 2000; >45: 408–9.
- Law D, Moore CB, Denning DW. Amphotericin B resistance testing of Candida spp.: a comparison of methods. J Ant imicrob Chemother 1997; >40: 109–12.